Stephen Braye

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Giuseppe Viale, Meredith M. Regan, Eugenio Maiorano et al. · Journal of Clinical Oncology · 2007 · 456 citations · Full text

Medicine, Endocrinology, Oncology +17

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

Giuseppe Viale, Anita Giobbie‐Hurder, Meredith M. Regan et al. · Journal of Clinical Oncology · 2008 · 343 citations · Full text

Medicine, Oncology, Pharmacology +15

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Olga Kondrashova, Monique Topp, Ksenija Nesic et al. · Nature Communications · 2018 · 292 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays

Meredith M. Regan, Giuseppe Viale, Mauro G. Mastropasqua et al. · JNCI Journal of the National Cancer Institute · 2006 · 167 citations · Full text

Medicine, Endocrinology, Oncology +15

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Birgitte Rasmussen, Meredith M. Regan, Anne E. Lykkesfeldt et al. · The Lancet Oncology · 2007 · 151 citations

Medicine, Gynecology, Oncology +17